Lupus Anticoagulant Positivity in Pediatric Patients With Prolonged Activated Partial Thromboplastin Time: A Single-Center Experience and Review of Literature

Pediatr Hematol Oncol. 2015;32(7):495-504. doi: 10.3109/08880018.2015.1065302. Epub 2015 Sep 18.

Abstract

The presence of lupus anticoagulants (LAs) is an important cause of activated partial thromboplastin time (aPTT) prolongation found in children after an infection or during screening tests before surgical intervention. The authors retrospectively reviewed the charts of 68 patients who have been consulted from surgery departments with prolonged aPTT. These patients were reevaluated with aPTT analysis after 1 week. Thirteen patients had normal aPTTs. Therefore, 55 patients remained with prolonged aPTTs. LA positivity was detected in 39 patients. Sixteen of these had prolonged aPTT prior to surgery (41%). Others with LA positivity had systemic lupus erythematosus (SLE; n = 6), infection (n = 5), leukemia (n = 3), hemolytic uremic syndrome (n = 2), epistaxis (n = 2), antiphospholipid syndrome (APS; n = 1), chronic immune thrombocytopenic purpura (n = 1), acute poststreptococcal glomerulonephritis (n = 1), central nervous system (CNS) thrombosis (n = 1), and congenital heart disease (n = 1). None of the patients had bleeding history. LA positivity rarely leads to bleeding and/or thrombosis. Specific therapy is usually not needed. Further prospective multicenter studies are required to understand clinical outcomes and laboratory correlation in children with positive LA.

Keywords: activated partial thromboplastin time; bleeding; children; lupus anticoagulant; thrombosis.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • Heart Defects, Congenital / blood*
  • Hematologic Diseases / blood*
  • Humans
  • Infant
  • Lupus Coagulation Inhibitor / blood*
  • Lupus Erythematosus, Systemic / blood*
  • Male
  • Partial Thromboplastin Time / methods
  • Thrombosis / blood*

Substances

  • Lupus Coagulation Inhibitor